Merck's Tulisokibart Hits Primary Goal in Mid-Stage Skin Disease Study

Merck has announced that its experimental skin disease treatment, tulisokibart, met its primary goal in a mid-stage study. The study involved patients with moderate-to-severe hidradenitis suppurativa, a chronic condition characterized by painful lumps and scarring.

The results showed that 72% of patients who received the highest dose of tulisokibart achieved at least a 50% reduction in inflammatory skin lesions after 16 weeks. In contrast, only 35% of patients on placebo experienced this level of improvement.

A more stringent measure, requiring a 75% reduction in lesions, was met by up to 41% of patients on the treatment, compared to just 15% on placebo. Merck also reported that safety outcomes were comparable between the treatment and placebo groups.